relmacabtagene autoleucel

{
  "id": "MLC-T-ONC-016484",
  "term": "relmacabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
  "synonyms": [
    "relma-cel",
    "autologous CD19-targeted CAR T cells JWCAR029",
    "autologous anti-CD19 CAR T cells JWCAR029"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/relmacabtagene-autoleucel/"
}